Stem Cell Clinic

CBG Called the ‘Stem Cell’ Of Cannabinoids and Could be More Profitable Than CBD – PRNewswire

PALM BEACH, Florida, May 11, 2020 /PRNewswire/ --The CBD market surge in the last few years has been well documented and all reports seem to project continued growth of revenues over the coming years.CNNsaid,"These hemp farmers are getting rich with CBD."For farmers, growing hemp is a booming business. And it's much more profitable than growing corn or soybeans. In the U.S., sales could surge from $591 million last year . . . to $22 billion within just three years." An articlefrom Wyatt Research added: "Today, CBD is getting most of the attention. For growers, the next generation of hemp will be even more profitable. It's called CBG. It's the precursor cannabinoid to both CBD and THC. And it's currently being researched for a wide range of uses including psoriasis, eczema and as a cosmetic additive. CBG is essentially the next type of cannabinoid that will be researched, developed and put into thousands of mainstream products. The article continued projecting that hemp growers will be getting into CBG: "Today, production of CBG is very low. And that means prices for CBG are five times higher than CBD! Consider these numbers: One acre of farmland planted for CBD will generate $61,380 in revenue. Yet that same acre planted with hemp for CBG will earn $306,900!". Active cannabis companies in the markets this week include: SponsorsOne Inc. (OTCPK: SPONF) (CSE: SPO), The Supreme Cannabis Company, Inc. (OTCQX: SPRWF) (TSX: FIRE), Cresco Labs Inc. (OTCQB: CRLBF) (CSE: CL), Aurora Cannabis Inc. (NYSE: ACB) (TSX: ACB), Aphria Inc. (NYSE: APHA) (TSX: APHA).

An articlein The Green Fund echoed those reports saying: "CBD or Cannabidiol, has taken the world by storm over the last few years, thanks to the introduction of the US Farm Bill in 2018. CBD has appeared in every product from coffee to cocktails, to even pet treats and beauty products. However, CBD isn't the only cannabinoid in town it's time to learn about CBG." The Green Fund commentary continued: "Although CBG is just hitting the markets, it was actually first discovered by researchers in the 1960's. CBG is the main element that the other cannabinoids are created from, hence being commonly referred to as the "stem cell."

SponsorsOne Inc. (OTCPK: SPONF) (CSE: SPO) BREAKING NEWS:SponsorsOne Introduces Oral Dissolving CBG Tablet - Company Adds Another CBG Product To Its GO Nutraceutical Branded Line Of "Cannabis 2.0" Products - SponsorsOne, acompany that utilizes its proprietary platform that combines digital marketing, wholesale and retail distribution, branding and operational & funding capital, giving it a competitive first mover advantage in rapidly building, launching and selling proprietary brands focused in the craft Alcohol, Functional Beverage and Cannabis Sectors, today announced that It has introduced another innovative CBG product, under the marketing management agreement with GO Nutraceutical's branded line of "Cannabis 2.0" products.

The company, which recently launched a line of flavored, chewable tablets delivering a 20mg dose of CBG, has now added a CBG sublingual dissolving tablet that delivers 10mg in a very small 6mm size also produced by GO Nutraceuticals. Sublingual dissolving tablets are placed under the tongue triggering much higher bioavailabilitywhich results in faster absorption into the body.

As with the chewable product, this will be sold direct to consumer through GO Nutraceuticals' online store and through SPO's wholesale and retail distribution channel and the company's rapidly expanding influencer network.

Myles Bartholomew, CEO of SponsorsOne, said: "Oral dissolving CBG tablets are one of the more unique offerings in our solid oral dose line. At 10mg and only 6mm round, the tiny size tablet melts perfectly in the mouth without the need for digestion. Oral dissolving tablets are new to the cannabis industry, but they are showing great potential. The product is easy and enjoyable to consume, the deliveries are small, and it tastes great. But it is not only our delivery system that is the key here, it is fact that we are utilizing CBG, which as we have said before, has been shown to possess enormous therapeutic promise, and has been called theholy grail of cannabinoids.We have taken the knowledge of the pharmaceutical industry and applied it to natural extracts to create the next innovative wave of cannabis deliveries. We believe this will help us separate the company from others in the market and will increase revenues and bring value to our shareholders." Read this and more news for SponsorsOne at: https://www.financialnewsmedia.com/news-spo/

Other recent developments in the cannabis/cbd/hemp industries:

The Supreme Cannabis Company, Inc. (OTCQX: SPRWF) (TSX: FIRE) recently announced the completion of its first international cannabis shipment fromCanadaintoIsrael. Supreme Cannabis partnered with Breath of Life International Ltd.("BOL Pharma"),Israel'slargest and leading producer of medical cannabis and cannabis products, to offer Truverra-branded premium medical cannabis to patients inIsrael.

"This transaction represents a new international revenue opportunity for Supreme Cannabis and builds Truverra's global medical brand in one of the most sophisticated medical cannabis markets in the world," saidColin Moore, Interim President and CEO of Supreme Cannabis. "With the support of BOL Pharma, we navigated bothCanadaandIsrael'scomplex regulatory landscapes to achieve compliance with regulatory authorities in both countries, including Health Canada, the Canadian Food Inspection Agency andIsrael'sMinistry of Health and Ministry of Agriculture and Rural Development. We benefitted from BOL Pharma's skilled team, international experience and solidified position as a leading medical cannabis company inIsrael. As we pursue capital-light international opportunities, we will continue to look toJeff Adams, Truverra's CEO, and his exceptional team to build Truverra's medical brand globally."

Cresco Labs Inc. (OTCQB: CRLBF) (CSE: CL) one of the largest vertically integrated multistate cannabis operators in the United States, recently announced that it has completed the expansion project for its cultivation and manufacturing facility located in Brookville, PA. The expansion project provides an additional 66,000 square feet of indoor and greenhouse cultivation area, bringing the total cultivation space1in the facility to 88,000 square feet. The Brookville site supplies Cresco's house of brands to 100% of the licensed dispensaries in Pennsylvania and the Company currently maintains one of the largest wholesale market shares.

The Company also concluded a significant expansion of its manufacturing capabilities with new and advanced extraction booths and integrated safety systems. The expansion project provides a 300% increase in capacity for butane extraction and a 90% increase in ethanol extraction which enables Cresco to efficiently process its increased biomass to manufacture its full portfolio of brands, including Cresco, Remedi and Reserve, with new brands launching soon. As a result of tripling the site's capacity in a phased approach, the Company expects products from the third, 22,000-square-foot phase to enter the market this month, with production from the fourth, 22,000-square-foot phase starting in July 2020 and gradually increasing throughout the remainder of the year.

Aurora Cannabis Inc. (NYSE: ACB) (TSX: ACB) the Canadian company defining the future of cannabis worldwide, recently provided an update related to its balance sheet flexibility, business transformation initiatives and COVID-19 operational response plans.

As ofMarch 31, 2020, the Company had approximately$205 millionof cash. This includes all amounts raised under the existing, and now completed,US$400 millionAt-the-Market Offering program ("ATM"), initially announced inMay 2019. To support the strength of the Company's balance sheet and provide continued access to equity capital, the Company today stated that it intends to file a new prospectus supplement for a renewed ATM program, to enable Aurora to raise additional equity capital pursuant to its outstanding base shelf prospectus datedMay 14, 2019under which approximatelyUS$350 millionremains available. The Company intends to use a portion of this available capacity to provide further balance sheet strength and preserve flexibility given macroeconomic uncertainty caused by COVID-19.

Aphria Inc. (NYSE: APHA) (TSX: APHA) recently announced that its subsidiary, ASG Pharma Ltd. ("ASG"), has received its European Union Good Manufacturing Practices ("EU GMP") certification from the Malta Medicines Authority("MMA") in respect of production of cannabis for medicinal and research purposes. Following receipt of its first medical cannabis import license for analytical testing and research in 2018 and the subsequent ASG facility upgrade, the certification provides Aphria with the ability to ship finished dried flower and finished oil for medicinal and research use in permitted jurisdictions throughout the European Union.

"We are pleased to receive EU GMP certification for ASG inMalta, our third facility to achieve this milestone, which really speaks to the Company's commitment to quality," saidIrwin D. Simon, Chief Executive Officer. "We remain excited about growth opportunities as this increases our ability to serve, and further strengthens Aphria's leadership, in the European Union."

DISCLAIMER: FN Media Group LLC (FNM), which owns and operates FinancialNewsMedia.com and MarketNewsUpdates.com, is a third party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels. FNM is NOT affiliated in any manner with any company mentioned herein. FNM and its affiliated companies are a news dissemination solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security. FNM's market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities. The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material. All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks. All material included herein is republished content and details which were previously disseminated by the companies mentioned in this release. FNM is not liable for any investment decisions by its readers or subscribers. Investors are cautioned that they may lose all or a portion of their investment when investing in stocks. For current services performed FNM has been compensated forty six hundred dollars for news coverage of the current press releases issued by SponsorsOne, Inc. by a non-affiliated. FNM HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.

This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company's annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and FNM undertakes no obligation to update such statements.

Media Contact email:[emailprotected]+1(561)325-8757

SOURCE FinancialNewsMedia.com

Link:
CBG Called the 'Stem Cell' Of Cannabinoids and Could be More Profitable Than CBD - PRNewswire

Were All Casualties of Trumps War on Coronavirus Science – The New York Times

In 2004, 60 Minutes aired a segment on what it called virus hunters, scientists searching for bugs that can leap from animals to humans and cause pandemics. What worries me the most is that we are going to miss the next emerging disease, said a scientist named Peter Daszak, describing his fear of a coronavirus that moves from one part of the planet to another, wiping out people as it moves along.

In the intervening years, Daszak became president of the EcoHealth Alliance, a nonprofit research organization focused on emerging pandemics. EcoHealth worked with Chinas Wuhan Institute of Virology to study coronaviruses in bats that could infect humans, and, as Science magazine put it, to develop tools that could help researchers create diagnostics, treatments and vaccines for human outbreaks. Since 2014, the EcoHealth Alliance has received a grant from the National Institutes of Health, until its funding was abruptly cut two weeks ago.

The reason, as 60 Minutes reported on Sunday evening, was a conspiracy theory spread by Representative Matt Gaetz, the Florida Republican who in March wore a gas mask on the House floor to mock concern about the new coronavirus. On April 14, Gaetz appeared on Tucker Carlsons Fox News show and claimed that the N.I.H. grant went to the Wuhan Institute, which Gaetz intimated might have been the source of the virus the institute may have birthed a monster, in his words.

The first of Gaetzs claims was flatly false, and the second unlikely; the C.I.A. has reportedly found no evidence of a link between the virus and the Wuhan lab. But at a White House briefing a few days later, a reporter from the right-wing website Newsmax told President Trump that under Barack Obama, the N.I.H. gave the Wuhan lab a $3.7 million grant. Why would the U.S. give a grant like that to China? she asked.

In fact, Trumps administration had recently renewed EcoHealths grant, but Trump didnt appear to know that. The Obama administration gave them a grant of $3.7 million? he asked. Then he said, We will end that grant very quickly.

And they did. But ending the grant dealt a blow to efforts to find treatments and a vaccine for the coronavirus. Remdesivir, the antiviral drug thats shown some promise in Covid-19 patients, was earlier tested against bat viruses EcoHealth discovered. Now the nonprofit is facing layoffs.

This political hit on Daszaks work is far from the only way that the Trump administrations contempt for science has undermined Americas coronavirus response. Conservative antipathy to science is nothing new; Republicans have long denied and denigrated the scientific consensus on issues from evolution to stem cell research to climate change. This hostility has several causes, including populist distrust of experts, religious rejection of information that undermines biblical literalism and efforts by giant corporations to evade regulation.

But its grown worse under Trump, with his authoritarian impulse to quash any facts, from inauguration crowd sizes to hurricane paths, that might reflect poorly on him.

Until recently, it seemed as if Trumps sabotage of efforts to combat climate change would be the most destructive legacy of his disregard for science. But the coronavirus has presented the country with an emergency that only sound science can solve. That means that the Trump administrations disdain for expertise, its elevation of slavish loyalty over technical competence, has become a more immediate threat.

Months before this pandemic began, Reuters reported, the Trump administration axed the job of an epidemiologist working for the Centers for Disease Control and Prevention in China to help detect emerging disease outbreaks. As the pandemic raged, the administration removed Rick Bright, one of Americas premier experts on vaccine development, from an agency overseeing efforts to develop a coronavirus vaccine. Last week Bright filed a whistle-blower complaint claiming hed suffered retaliation because he resisted funding potentially dangerous drugs promoted by those with political connections and by the administration itself. (A federal watchdog agency has called for him to be reinstated pending its investigation.)

Another whistle-blower complaint, filed by a former volunteer on the coronavirus team assembled by Trumps son-in-law, Jared Kushner, claims the effort has been beset by inexperience and incompetence. The Associated Press reported on how the White House buried guidance from the C.D.C. on how communities could safely reopen. Now the president is urging Americans to return to work even as the White House itself has proved unable to keep the coronavirus at bay.

According to Axios, Trump has even privately started expressing skepticism of the coronaviruss death toll, suggesting its lower than official statistics say. (Most experts believe the opposite.) A senior administration official said he expects the president to begin publicly questioning the death toll as it closes in on his predictions for the final death count and damages him politically, reported Axios. The Trump administrations approach to the coronavirus began with denialism, and thats likely how it will end.

Any progress America makes in fighting Covid-19 will be in spite of its federal government, not because of it. I am speaking out because to combat this deadly virus, science not politics or cronyism has to lead the way, Dr. Bright said when he went public with his complaint in April. Trump wont let that happen. Hed rather essentially give up on combating it at all.

Visit link:
Were All Casualties of Trumps War on Coronavirus Science - The New York Times

Rocket Pharmaceuticals Presents Positive Updates on FA and LAD-I Gene Therapy Programs at the 23rd Annual Meeting of the American Society of Gene and…

NEW YORK--(BUSINESS WIRE)--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) (Rocket), a clinical-stage company advancing an integrated and sustainable pipeline of genetic therapies for rare disorders, today presents new clinical data supporting longer-term efficacy and durability of gene therapy for Fanconi Anemia (FA) and Leukocyte Adhesion Deficiency-I (LAD-I) at the 23rd Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT) being held virtually May 12-15, 2020. Two oral presentations highlight updates from the companys Phase 1/2 study of RP-L201 for the treatment of severe LAD-I and the Phase 1/2 study of RP-L102 Process A for the treatment of FA.

The latest additional data from both our LAD-I and FA programs demonstrate sustained engraftment and durable clinical impact, said Jonathan D. Schwartz, M.D., Chief Medical Officer and Senior Vice President of Rocket. These results further support the viability of gene therapy in LAD-I and FA, disorders in which bone marrow transplant is the primary curative option and is associated with high rates of toxicity.

Patients with severe LAD-I have neutrophil CD18 expression of less than 2% of normal, with extremely high mortality in early childhood, said Dr. Schwartz. In this first patient treated with RP-L201 using Process B, an increase from less than 1% to 47% CD18 expression sustained over six months demonstrates that RP-L201 has the potential to correct the neutrophil deficiency that is the hallmark of LAD-I. We are also pleased with the continued visible improvement of multiple disease-related skin lesions. These results lend further support to the applicability of Process B across the lentiviral portfolio. The second patient has also recently been treated, and we look forward to completing the Phase 1 portion of the registrational trial for this program.

Dr. Schwartz continued, In our FA program, patients followed for a year or more after treatment with RP-L102 Process A continue to demonstrate durable engraftment and hematologic correction, without the use of pre-treatment conditioning regimens. All six patients who received minimally adequate drug product and were followed for more than one year display sustained and progressive engraftment. Notably, hemoglobin levels have normalized to baseline in two patients treated. Todays update not only gives us confidence as we transition to our improved Process B drug product, but also supports the potential of gene therapy in the absence of any conditioning regimen as a definitive hematologic treatment for FA. The ability to treat patients without the side effects associated with allogeneic transplant or the use of genotoxic conditioning, and to restore blood cell counts is a major milestone for the FA scientific community.

Details on Rockets oral presentations at ASGCT:

Title: A Phase 1/2 Study of Lentiviral-mediated Ex-vivo Gene Therapy for Pediatric Patients with Severe Leukocyte Adhesion Deficiency-I (LAD-I): Initial Results from the First Treated Patient Session: HSPC Gene Therapies for Blood and Immune DisordersPresenter: Donald B. Kohn, M.D., Professor of Microbiology, Immunology and Molecular Genetics, Pediatrics (Hematology/Oncology), Molecular and Medical Pharmacology, member of the Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research at UCLA and principal investigator of the Phase 1 trialDate: Tuesday May 12, 2020Time: 4:30 p.m. - 4:45 p.m. EDT

Additional results from the first patient treated with RP-L201 for LAD-I continue to demonstrate evidence of safety and potential efficacy. Analyses of peripheral vector copy number (VCN) and CD18-expressing neutrophils were performed six months post treatment with RP-L201 to evaluate engraftment and phenotypic correction. The patient demonstrated peripheral blood VCN levels of 1.3 and CD18-expression of 47%, which is sustained from the 45% expression observed three months post treatment; pretreatment CD18 expression was <1%. The drug product VCN was 3.8. Additionally, the patient continues to display visible improvement of skin lesions. No safety or tolerability issues related to RP-L201 administration have been identified to date.

RP-L201 was in-licensed from the Centro de Investigaciones Energticas, Medioambientales y Tecnolgicas (CIEMAT), Centro de Investigacin Biomdica en Red de Enfermedades Raras (CIBERER) and Instituto de Investigacin Sanitaria Fundacin Jimnez Daz (IIS-FJD). The lentiviral vector was developed in a collaboration between The University College of London (UCL) and CIEMAT.

Title: Updated Results of a European Gene Therapy Trial in Fanconi Anemia Patients, Subtype ASession: HSPC Gene Therapies for Blood and Immune DisordersPresenter: Juan A. Bueren, Ph.D., Scientific Director of the FA gene therapy program and Head of the Hematopoietic Innovative Therapies Division at CIEMAT in Spain / CIBERER / IIS-FJD Date: Tuesday May 12, 2020Time: 4:45 p.m. - 5:00 p.m. EDT

Nine pediatric patients have been enrolled and treated in the Phase 1/2 clinical trial of RP-L102 Process A for the treatment of Fanconi Anemia, seven of whom are evaluable at or beyond the one year mark following treatment. The first four patients (02002, 02004, 02005 and 02006) exhibit robust and durable engraftment, continued hematologic correction and blood count stabilization. Importantly, hemoglobin levels for patients 02002 and 02006 have increased to a healthy, normal range; these patients received more optimal product consistent with the minimal dose criteria established for the Process B registrational program. Two additional patients (02008 and 02013) who have been followed for a year or more after treatment display early evidence of engraftment, as measured by increases in peripheral blood VCNs. Patient 02007 received a lower than optimal dose and is beginning to demonstrate preliminary signs of engraftment. Blood counts are not yet available in these patients. Two patients, patients 01003 and 02009, have not been included in this analysis. Patient 02009 is only six months post treatment and will continue to be followed. Patient 01003 received a drug product that did not meet full release criteria due to a technical issue this was a one-time lab-specific issue that was addressed. To date, no patients in this trial have undergone allogeneic bone marrow transplant.

RP-L102 is being developed in conjunction with CIEMAT, CIBERER and IIS-FJD.

The presentations will be made available on Rockets website at http://www.rocketpharma.com/asgct-presentations/ following presentation at the conference.

About Leukocyte Adhesion Deficiency-ISevere Leukocyte Adhesion Deficiency-I (LAD-I) is a rare, autosomal recessive pediatric disease caused by mutations in the ITGB2 gene encoding for the beta-2 integrin component CD18. CD18 is a key protein that facilitates leukocyte adhesion and extravasation from blood vessels to combat infections. As a result, children with severe LAD-I are often affected immediately after birth. During infancy, they suffer from recurrent life-threatening bacterial and fungal infections that respond poorly to antibiotics and require frequent hospitalizations. Children who survive infancy experience recurrent severe infections including pneumonia, gingival ulcers, necrotic skin ulcers, and septicemia. Without a successful bone marrow transplant, mortality in patients with severe LAD-I is 60-75% prior to the age of 2 and survival beyond the age of 5 is uncommon. There is a high unmet medical need for patients with severe LAD-I.

Rockets LAD-I research is made possible by a grant from the California Institute for Regenerative Medicine (Grant Number CLIN2-11480). The contents of this press release are solely the responsibility of Rocket and do not necessarily represent the official views of CIRM or any other agency of the State of California.

About Fanconi AnemiaFanconi Anemia (FA) is a rare pediatric disease characterized by bone marrow failure, malformations and cancer predisposition. The primary cause of death among patients with FA is bone marrow failure, which typically occurs during the first decade of life. Allogeneic hematopoietic stem cell transplantation (HSCT), when available, corrects the hematologic component of FA, but requires myeloablative conditioning. Graft-versus-host disease, a known complication of allogeneic HSCT, is associated with an increased risk of solid tumors, mainly squamous cell carcinomas of the head and neck region. Approximately 60-70% of patients with FA have a Fanconi Anemia complementation group A (FANCA) gene mutation, which encodes for a protein essential for DNA repair. Mutation in the FANCA gene leads to chromosomal breakage and increased sensitivity to oxidative and environmental stress. Increased sensitivity to DNA-alkylating agents such as mitomycin-C (MMC) or diepoxybutane (DEB) is a gold standard test for FA diagnosis. Somatic mosaicism occurs when there is a spontaneous correction of the mutated gene that can lead to stabilization or correction of a FA patients blood counts in the absence of any administered therapy. Somatic mosaicism, often referred to as natural gene therapy provides a strong rationale for the development of FA gene therapy because of the selective growth advantage of gene-corrected hematopoietic stem cells over FA cells1.

1Soulier, J.,et al. (2005) Detection of somatic mosaicism and classification of Fanconi anemia patients by analysis of the FA/BRCA pathway. Blood 105: 1329-1336

About Rocket Pharmaceuticals, Inc.Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) (Rocket) is advancing an integrated and sustainable pipeline of genetic therapies that correct the root cause of complex and rare disorders. The companys platform-agnostic approach enables it to design the best therapy for each indication, creating potentially transformative options for patients afflicted with rare genetic diseases. Rocket's clinical programs using lentiviral vector (LVV)-based gene therapy are for the treatment of Fanconi Anemia (FA), a difficult to treat genetic disease that leads to bone marrow failure and potentially cancer, Leukocyte Adhesion Deficiency-I (LAD-I), a severe pediatric genetic disorder that causes recurrent and life-threatening infections which are frequently fatal, and Pyruvate Kinase Deficiency (PKD) a rare, monogenic red blood cell disorder resulting in increased red cell destruction and mild to life-threatening anemia. Rockets first clinical program using adeno-associated virus (AAV)-based gene therapy is for Danon disease, a devastating, pediatric heart failure condition. Rockets pre-clinical pipeline program is for Infantile Malignant Osteopetrosis (IMO), a bone marrow-derived disorder. For more information about Rocket, please visit http://www.rocketpharma.com.

Rocket Cautionary Statement Regarding Forward-Looking StatementsVarious statements in this release concerning Rocket's future expectations, plans and prospects, including without limitation, Rocket's expectations regarding its guidance for 2020 in light of COVID-19, the safety, effectiveness and timing of product candidates that Rocket may develop, to treat Fanconi Anemia (FA), Leukocyte Adhesion Deficiency-I (LAD-I), Pyruvate Kinase Deficiency (PKD), Infantile Malignant Osteopetrosis (IMO) and Danon Disease, and the safety, effectiveness and timing of related pre-clinical studies and clinical trials, may constitute forward-looking statements for the purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995 and other federal securities laws and are subject to substantial risks, uncertainties and assumptions. You should not place reliance on these forward-looking statements, which often include words such as "believe," "expect," "anticipate," "intend," "plan," "will give," "estimate," "seek," "will," "may," "suggest" or similar terms, variations of such terms or the negative of those terms. Although Rocket believes that the expectations reflected in the forward-looking statements are reasonable, Rocket cannot guarantee such outcomes. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including, without limitation, Rocket's ability to monitor the impact of COVID-19 on its business operations and take steps to ensure the safety of patients, families and employees, the interest from patients and families for participation in each of Rockets ongoing trials, our expectations regarding when clinical trial sites will resume normal business operations, our expectations regarding the delays and impact of COVID-19 on clinical sites, patient enrollment, trial timelines and data readouts, our expectations regarding our drug supply for our ongoing and anticipated trials, actions of regulatory agencies, which may affect the initiation, timing and progress of pre-clinical studies and clinical trials of its product candidates, Rocket's dependence on third parties for development, manufacture, marketing, sales and distribution of product candidates, the outcome of litigation, and unexpected expenditures, as well as those risks more fully discussed in the section entitled "Risk Factors" in Rocket's Quarterly Report on Form 10-Q for the quarter ended March 31, 2020, filed May 8, 2020 with the SEC. Accordingly, you should not place undue reliance on these forward-looking statements. All such statements speak only as of the date made, and Rocket undertakes no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise.

Original post:
Rocket Pharmaceuticals Presents Positive Updates on FA and LAD-I Gene Therapy Programs at the 23rd Annual Meeting of the American Society of Gene and...

Cell Expansion Market : Facts, Figures and Analytical Insights 2020-2026 – Cole of Duty

The report provides a valuable source of insightful data for business strategists and competitive analysis of Cell Expansion Market. It provides the Cell Expansion industry overview with growth analysis and futuristic cost, revenue and many other aspects. The research analysts provide an elaborate description of the value chain and its distributor analysis. This Tire Cell Expansion study provides comprehensive data which enhances the understanding, scope and application of this report.

the cell expansion market is projected to display a robust growth represented by a CAGR of 17.33% during 2019 2024.

A comprehensive research report created through extensive primary research (inputs from industry experts, companies, stakeholders) and secondary research, the report aims to present the analysis of cell expansion market. The report analyses the Global Cell Expansion Market: Analysis By Product Type (Instruments, Consumables, Disposables), By Cell Type (Human Cell and Animal Cell), By Application (Regenerative Medicine & Stem Cell Research and Cancer & Cell Based Research), By Region (North America, Europe, Asia Pacific, South America, and Middle East & Africa), (U.S, Canada, Germany, France, U.K., Japan, China, India): Opportunities and Forecast (2019 Edition): Forecast to 2024, for the historical period of 2018-2019 and the forecast period of 2019-2024.

Inquire for Sample Copy of this Report at:

https://bit.ly/35chcJP

Prominent Players in the global Cell Expansion market are

Merck Millipore, Eppendorf, ThermoFisher Scientific, Becton Dickinson, Danaher Corporation, Corning Inc., Terumo Medical Corporation, CellGenix Technologie Transfer GmbH, Synthecon Inc., Stem Cell Technologies Inc.

SAN ANTONIO Oct. 8, 2019 Southwest Research Institute has received new funding from the Medical Technology Enterprise Consortium (MTEC) and the Food and Drug Administration (FDA) to use an SwRI-developed bioreactor to propagate cells for personalized regenerative medicine applications. A $3 million MTEC program will demonstrate stem cell manufacturing, and a $2.3 FDA contract is funding CAR T-cell production. Cell and gene therapies hold the promise of revolutionizing treating diseases using a patients own immune or stem cells. But existing technologies dont meet clinical needs for high-quality and cost-effective cell manufacturing. They typically require an expensive, labor-intensive cell culture process in high-cost clean room conditions.

Jun 13, 2013: Merck Millipore has announced the availability of its PluriSTEM Human ES/iPS Medium for the routine expansion of human embryonic and induced pluripotent stem cells in feeder- and serum-free conditions with less frequent feeding and cell culture time.

It is the first human ES/iPS media to combine small molecule inhibitors with pluripotent specific growth factors and supplements to enable a less rigorous cell culture regiment. These features save researchers time and lead to lower costs.

Scope of the Report

-Cell Expansion Market Size, Share & Forecast-Segmental Analysis Standalone and Chained Chained/Organized Cell Expansion Sizing, Growth, Forecast-Market Entry Strategies for Domestic/Foreign Players-Policy & Regulatory Landscape-Changing Market Trends & Emerging Opportunities-Competitive Landscape & Strategic Recommendations

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.

Buy Report Now:

https://bit.ly/2W41aOb

What are the market factors that are explained in the report?

Key Strategic Developments:The study also includes the key strategic developments of the market, comprising R&D, new product launch, M&A, agreements, collaborations, partnerships, joint ventures, and regional growth of the leading competitors operating in the market on a global and regional scale.

Analytical Tools:The Global Cell Expansion Market Report includes the accurately studied and assessed data of the key industry players and their scope in the market by means of a number of analytical tools. The analytical tools such as Porters five forces analysis, SWOT analysis, feasibility study, and investment return analysis have been used to analyze the growth of the key players operating in the market.

Key Market Features:The report evaluated key market features, including revenue, price, capacity, capacity utilization rate, gross, production, production rate, consumption, import/export, supply/demand, cost, market share, CAGR, and gross margin. In addition, the study offers a comprehensive study of the key market dynamics and their latest trends, along with pertinent market segments and sub-segments.

We Offer Customization on report based on specific client Requirement:

Free country Level analysis for any 5 countries of your choice. Free Competitive analysis of any 5 key market players. Free 40 analyst hours to cover any other data point.

Browse Full Report at:

https://bit.ly/2yPtGLk

How we have factored the effect of Covid-19 in our report:

All the reports that we list have been tracking the impact of COVID-19. Both upstream and downstream of the entire supplychain has been accounted for while doing this. Also, where possible, we will provide an additional COVID-19 update supplement/report to the report in Q3, please check for with the sales team.

ABOUT US:

MarketInsightsReports provides syndicated market research on industry verticals including Healthcare, Information and Communication Technology (ICT), Technology and Media, Chemicals, Materials, Energy, Heavy Industry, etc. MarketInsightsReports provides global and regional market intelligence coverage, a 360-degree market view which includes statistical forecasts, competitive landscape, detailed segmentation, key trends, and strategic recommendations.

Contact US:

Irfan Tamboli (Head of Sales)

Market Insights Reports

Phone: + 1704 266 3234 | Mob: +91-750-707-8687

[emailprotected] | [emailprotected]

See the original post here:
Cell Expansion Market : Facts, Figures and Analytical Insights 2020-2026 - Cole of Duty

Global Stem Cell Partnering Terms and Agreements 2010-2020 – stopthefud

Bharat Book Bureau Provides the Trending Market Research Report on Global Stem Cell Partnering Terms and Agreements 2010-2020under Life Sciences Category. The report offers a collection of superior market research, market analysis, competitive intelligence and Market reports.

The Global Stem Cell Partnering Market Terms and Agreements 2010-2020 report provides comprehensive understanding and unprecedented access to the stem cell partnering deals and agreements entered into by the worlds leading healthcare companies.

The report provides a detailed understanding and analysis of how and why companies enter Stem Cell partnering deals. These deals tend to be multicomponent, starting with collaborative R&D, and proceed to commercialization of outcomes.

Request a free sample copy of Stem Cell Partnering Market Report @

https://www.bharatbook.com/marketreports/sample/reports/166796

Trends in stem cell partneringDeal terms analysisPartnering agreement structurePartnering contract documentsTop deals by valueMost active dealmakersAverage deal terms for stem cells

This report provides details of the latest Stem Cell agreements announced in the life sciences since 2010.

The report takes the reader through a comprehensive review Stem Cell deal trends, key players, top deal values, as well as deal financials, allowing the understanding of how, why and under what terms, companies are entering Stem Cell partnering deals.

The report presents financial deal term values for Stem Cell deals, listing by headline value, upfront payments, milestone payments and royalties, enabling readers to analyse and benchmark the financial value of deals.

The middle section of the report explores the leading dealmakers in the Stem Cell partnering field; both the leading deal values and most active Stem Cell dealmaker companies are reported allowing the reader to see who is succeeding in this dynamic dealmaking market.

One of the key highlights of the report is that over 600 online deal records of actual Stem Cell deals, as disclosed by the deal parties, are included towards the end of the report in a directory format by company A-Z, stage of development, deal type, therapy focus, and technology type that is easy to reference. Each deal record in the report links via Weblink to an online version of the deal.

In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners. Whilst many companies will be seeking details of the payment clauses, the devil is in the detail in terms of how payments are triggered contract documents provide this insight where press releases and databases do not.

The initial chapters of this report provide an orientation of Stem Cell dealmaking. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in Stem Cell dealmaking since 2010, including details of headline, upfront, milestone and royalty terms.

Chapter 3 provides a review of the leading Stem Cell deals since 2010. Deals are listed by headline value. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 4 provides a comprehensive listing of the top 25 most active companies in Stem Cell dealmaking with a brief summary followed by a comprehensive listing of Stem Cell deals announded by that company, as well as contract documents, where available.

Chapter 5 provides a comprehensive and detailed review of Stem Cell partnering deals signed and announced since Jan 2010, where a contract document is available in the public domain. Each deal title links via Weblink to an online version of the deal record and contract document, providing easy access to each contract document on demand.

Chapter 6 provides a comprehensive and detailed review of Stem Cell partnering deals signed and announced since Jan 2010. The chapter is organized by specific Stem Cell technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each deal on demand.

A comprehensive series of appendices is provided organized by Stem Cell partnering company A-Z, stage of development, deal type, and therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each deal on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in Stem Cell partnering and dealmaking since 2010.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Stem Cell technologies and products.

Key benefits

Global Stem Cell Partnering Terms and Agreements 2010-2020 provides the reader with the following key benefits:

In-depth understanding of Stem Cell deal trends since 2010Access to headline, upfront, milestone and royalty dataAnalysis of the structure of Stem Cell agreements with numerous real life case studiesDetailed access to actual Stem Cell contracts entered into by leading biopharma companiesIdentify most active Stem Cell dealmakers since 2010Insight into terms included in a Stem Cell partnering agreement, with real world examplesUnderstand the key deal terms companies have agreed in previous dealsUndertake due diligence to assess suitability of your proposed deal terms for partner companies

Report scope

Global Stem Cell Partnering Terms and Agreements 2010-2020 is intended to provide the reader with an in-depth understanding and access to Stem Cell trends and structure of deals entered into by leading companies worldwide.

Stem Cell Partnering Terms and Agreements includes:

Trends in Stem Cell dealmaking in the biopharma industry since 2010Analysis of Stem Cell deal structureAccess to headline, upfront, milestone and royalty dataCase studies of real-life Stem Cell dealsAccess to Stem Cell contract documentsLeading Stem Cell deals by value since 2010Most active Stem Cell dealmakers since 2010

In Global Stem Cell Partnering Terms and Agreements 2010-2020, the available deals are listed by:

Company A-ZHeadline valueStage of development at signingDeal component typeSpecific therapy targetTechnology type

Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The Global Stem Cell PartneringTerms and Agreements 2010-2020 report provides comprehensive access to available deals and contract documents for over 600 Stem Cell deals.

Analyzing actual contract agreements allows assessment of the following:

What are the precise rights granted or optioned?What is actually granted by the agreement to the partner company?What exclusivity is granted?What is the payment structure for the deal?How are sales and payments audited?What is the deal term?How are the key terms of the agreement defined?How are IPRs handled and owned?Who is responsible for commercialization?Who is responsible for development, supply, and manufacture?How is confidentiality and publication managed?How are disputes to be resolved?Under what conditions can the deal be terminated?What happens when there is a change of ownership?What sublicensing and subcontracting provisions have been agreed?Which boilerplate clauses does the company insist upon?Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?Which jurisdiction does the company insist upon for agreement law?

Browse our full report with Table of Content :https://www.bharatbook.com/marketreports/global-stem-cell-partnering-terms-and-agreements-2010-2020/166796

About Bharat Book Bureau:

Bharat Book is Your One-Stop-Shop with an exhaustive coverage of 4,80,000 reports and insights that includes latest Market Study, Market Trends & Analysis, Forecasts Customized Intelligence, Newsletters and Online Databases. Overall a comprehensive coverage of major industries with a further segmentation of 100+ subsectors.

Contact us at:

Bharat Book Bureau

Tel: +91 22 27810772 / 27810773

Email: poonam@bharatbook.com

Website: http://www.bharatbook.com

Like Loading...

Related

Visit link:
Global Stem Cell Partnering Terms and Agreements 2010-2020 - stopthefud